Over the past decades, significant progress has been made in understanding the pathogenesis of chronic inducible urticaria (CIndU). Provocation tests continue to play an important role in confirming the diagnosis. For patients who do not achieve disease control despite H1 antihistamines or omalizumab, numerous biologics and small molecules are currently being investigated in clinical trials, most – but not all – of which are directed against new therapeutic targets.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Atopic dermatitis
Clinic, therapy and prevention in early childhood
- Prevention of skin cancer
UV protection and skin cancer screening – Update 2025
- Electrolyte disturbance
Hyponatremia in the outpatient setting
- Pain and autism
Hurdles to pain treatment for autistic patients
- Chronic musculoskeletal pain
How can the use of analgesics be optimized in multimodal therapy?
- Findings from the TRACK-FA study
Neuroimaging biomarkers in Friedreich’s ataxia
- Chronic inducible urticaria
What has stayed the same, what has changed?
- Case study